"label","id","name","text","uuid:ID","description","instanceType"
"","Objective_1","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","c863cdc8-eccb-41b0-8989-f13142425302","Main objective","Objective"
"","Objective_2","OBJ2","To document the safety profile of the xanomeline TTS.","bbff911d-bb81-42f4-b459-30740b1409f3","Safety","Objective"
"","Objective_3","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","8086a269-0cb4-482e-ae67-91526ac537c2","Behaviour","Objective"
"","Objective_4","OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","a2bcd406-07d9-4539-8b1e-f4a7460df88a","","Objective"
"","Objective_5","OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","000b8f80-9d66-448a-9bb3-a43f2b2dd57c","","Objective"
"","Objective_6","OBJ6","To assess the treatment response as a function of Apo E genotype.","b481c883-6d72-4d6c-bcf9-897a34545e23","","Objective"
